NCT04510051View on ClinicalTrials.gov

CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 4, 2020

Primary Completion Date

February 10, 2026

Study Completion Date

February 10, 2026

Conditions
Malignant Brain NeoplasmRecurrent Malignant Brain NeoplasmRefractory Malignant Brain Neoplasm
Interventions
DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine

Given IV

BIOLOGICAL

IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes

Given intraventricularly

Trial Locations (3)

48109

RECRUITING

C.S. Mott Children's Hospital, University of Michigan, Ann Arbor

90027

RECRUITING

Children's Hospital Los Angeles, Los Angeles

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER